Efficacy of Hydroxychloroquine for Improving Pregnancy Outcomes in a Female with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Yumika Takaki, Atsushi Daimon, Misa Nunode, Tomohito Tanaka, Daisuke Fujita, and Masahide Ohmichi

Department of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka 569-8686, Japan

Correspondence should be addressed to Yumika Takaki; yumika.takaki@ompu.ac.jp and Atsushi Daimon; atsushi.daimon@ompu.ac.jp

Received 23 May 2022; Accepted 5 August 2022; Published 21 August 2022

Copyright © 2022 Yumika Takaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The use of heparin and low-dose aspirin is the current conventional treatment for pregnant females with antiphospholipid syndrome (APS). However, there is no additional treatment recommended for cases where the standard treatment cannot prevent obstetric complications such as fetal loss and placental insufficiency. Recently, the addition of a novel antimalarial, hydroxychloroquine (HCQ), to the conventional treatment has shown the potential to prevent obstetric complications. Herein, we report a case in which the addition of HCQ improved adverse pregnancy outcomes in a pregnant female with systemic lupus erythematosus and aspirin-heparin-resistant APS.

1. Introduction

Females with antiphospholipid syndrome (APS) have an increased risk of thrombosis and pregnancy complications, such as recurrent early miscarriages and hypertensive disorders of pregnancy [1]. The use of heparin and low-dose aspirin (LDA) is the current conventional treatment for pregnant females with APS and has improved pregnancy outcomes to a live birth rate of >70% [2, 3]. Recently, an antimalarial drug, hydroxychloroquine (HCQ), was recommended, besides the conventional treatment in patients with APS and previous pregnancy failure on current therapy for APS [4]. Herein, we report a case of systemic lupus erythematosus (SLE) and aspirin-heparin-resistant APS successfully treated with HCQ in addition to the patient’s existing therapy.

2. Case Presentation

A 35-year-old pregnant female (gravida 4, parity 1) with SLE without lupus nephritis and APS visited our hospital at 6 weeks of gestation (GW). The patient was diagnosed with SLE without lupus nephritis and was positive for antiphospholipid antibody (aPL), including lupus anticoagulant, anticardiolipin antibody, and antiphosphatidylserine/prothrombin antibodies at 18 years old. The patient’s pregnancy history is presented in Table 1. The first pregnancy resulted in an APS diagnosis. The SLE remained in remission, and this case was diagnosed as an aspirin-heparin-resistant APS based on the patient’s pregnancy history. Consequently, for the fourth pregnancy, HCQ was commenced before conception with the patient’s informed consent. Immediately after a positive pregnancy test was obtained, warfarin was
discontinued. Following that, the 6 GW embryo was confirmed, therapeutic doses of unfractionated heparin (UFH) (15,000 units/day, subcutaneously) were introduced, and intravenous immunoglobulin therapy (IVIg) (25 g/day for 5 consecutive days; total dose: 125 g) was administered without adverse effects. LDA was maintained until 34 GW, and the fetal growth was appropriate for the gestational age. However, the patient’s platelet count decreased from 27.2 × 10^4/μL at 6 GW to 16.5 × 10^4/μL at 34 GW, and the maternal blood pressure was elevated to 133/90 mmHg (Figure 1). Contrarily, the serum C3 levels did not decrease during this pregnancy (Figure 1). The platelet count further decreased to 14.4 × 10^4/μL at 35 GW (Figure 1), and we assessed that the patient’s condition had worsened. Therefore, a cesarean section was performed, and a male infant weighing 2,618 g was delivered. Continuous heparin infusion was initiated 12 h after cesarean section and continued for 5 days. On postpartum day 1, LDA (100 mg/day) and warfarin (5 mg/day) were restarted. The patient and infant were discharged without complications on postpartum day 6.

### 3. Discussion

This case of treatment-resistant APS with SLE was treated successfully with HCQ, LDA, therapeutic doses of UFH, prednisolone (PSL), tacrolimus, and IVIg at 6 GW. Not only autoimmune diseases, such as SLE and APS [1], but also other proinflammatory diseases, such as endometriosis [5] and polycystic ovary syndrome [6], are known to influence the reproductive outcomes. Despite receiving conventional therapy, 20–30% of females with APS continue to experience pregnancy complications. Attempts have been made to add PSL [7] or IVIg [8] to the conventional treatment; however, the best approach to improve the outcomes of these pregnancies is unknown. Recently, novel drugs, including HCQ [9] and pravastatin [10], have been considered for preventing adverse pregnancy outcomes. HCQ was recommended in addition to the conventional therapy in patients with APS and previous pregnancy failure receiving the standard treatment [4]. Thus, HCQ may benefit patients with thrombotic and obstetric APS.

| Table 1: Patient’s pregnancy history. |
|---------------------------------------|
| **First pregnancy**                  |
| Age (y) 28 PSL (9 mg/day) LDA (100 mg/day) UFH (10,000 units/day) |
| Medication during pregnancy           |
| Complication: mother                  |
| Complication: infant                  |
| Gestational age at delivery (GW)      |
| Birth weight (g)                      |
| **Second pregnancy**                 |
| Age (y) 31 PSL (15 mg/day) LDA (100 mg/day) UFH (10,000 units/day) |
| Medication during pregnancy           |
| Complication: mother                  |
| Complication: infant                  |
| Gestational age at delivery (GW)      |
| Birth weight (g)                      |
| **Third pregnancy**                  |
| Age (y) 34 PSL (12 mg/day) LDA (100 mg/day) TAC (4 mg/day) |
| Medication during pregnancy           |
| Complication: mother                  |
| Complication: infant                  |
| Gestational age at delivery (GW)      |
| Birth weight (g)                      |

PSL: prednisolone; LDA: low-dose aspirin; UFH: unfractionated heparin; TAC: tacrolimus; FGR: fetal growth restriction; IUFD: intrauterine fetal demise; HELLP: hemolysis, elevated liver enzymes, and low platelets; GW: gestational week; IVIg: intravenous immunoglobulin.

**Figure 1:** Changes in blood pressure and blood sampling data.
Several studies have investigated the mechanism by which HCQ exerts an antithrombotic effect. In vitro, HCQ inhibited platelet aggregation and the release of arachidonic acid from aPL-induced stimulated platelets [11]. In vivo, in patients with aPL and APS, HCQ restored the destruction of the anticoagulant annexin A5 [12] and decreased soluble tissue factor [13]. The obstetric effects of HCQ have been reported in experiments with mice. In an aPL-induced fetal loss mouse model, HCQ prevented fetal death, increased placental and fetal weight, and decreased placental superoxide production, which is a marker of oxidative stress [14]. In vitro, HCQ significantly reduced the induction of endosomal nicotinamide adenine dinucleotide phosphate (NADPH), an enzyme complex involved in proinflammatory signaling pathways [15]. Clinically, HCQ is expected to prevent aPL-related adverse pregnancy outcomes, including first-trimester miscarriages and ischemic placental-mediated complications, such as preeclampsia and fetal growth restriction [9, 16].

In conclusion, HCQ may be useful in improving pregnancy outcomes in patients with previous pregnancy failure receiving the current conventional treatment for APS.

**Data Availability**

Data is available upon request by emailing atushi.daimon@ompu.ac.jp.

**Conflicts of Interest**

The authors declare that there is no conflict of interest regarding the publication of this article.

**Authors’ Contributions**

The authors alone are responsible for the content and writing of this manuscript.

**Acknowledgments**

We would like to thank Editage (http://www.editage.com) for English language editing.

**References**

[1] K. Schreiber and B. J. Hunt, “Managing antiphospholipid syndrome in pregnancy,” *Thrombosis Research*, vol. 181, Suppl 1, pp. S41–S46, 2019.

[2] G. Espinosa and R. Cervera, “Current treatment of antiphospholipid syndrome: lights and shadows,” *Nature Reviews Rheumatology*, vol. 11, no. 10, pp. 586–596, 2015.

[3] M. Empson, M. Lassere, J. C. Craig, R. Scott, and Cochrane Pregnancy and Childbirth Group, “Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant,” *Cochrane Database of Systematic Reviews*, vol. 2012, no. 2, article CD002859, 2012.

[4] S. Sciascia, D. W. Branch, R. A. Levy et al., “The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies,” *Thrombosis and Haematostasis*, vol. 115, no. 2, pp. 285–290, 2016.

[5] V. Šalamun, I. Verdenik, A. S. Lagană, and E. Vrtačnik-Bokal, “Should we consider integrated approach for endometriosis-associated infertility as gold standard management? Rationale and results from a large cohort analysis,” *Archives of Gynecology and Obstetrics*, vol. 297, no. 3, pp. 613–621, 2018.

[6] M. N. D’Alterio, M. Sigilli, A. G. Succu et al., “Pregnancy outcomes in women with polycystic ovarian syndrome,” *Minerva Obstetrica and Gynecology*, vol. 74, no. 1, pp. 45–59, 2022.

[7] K. Bramham, M. Thomas, C. Nelson-Piercy, M. Khamashtha, and B. J. Hunt, “First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss,” *Blood*, vol. 117, no. 25, pp. 6948–6951, 2011.

[8] S. Shimada, H. Yamada, T. Atsumi, T. Yamada, N. Sakuragi, and H. Minakami, “Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome,” *Reproductive Medicine and Biology*, vol. 9, no. 4, pp. 217–221, 2010.

[9] S. Sciascia, B. J. Hunt, E. Talavera-Garcia, G. Lliso, M. A. Khamashtha, and M. J. Cuadrado, “The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies,” *American Journal of Obstetrics and Gynecology*, vol. 214, no. 2, pp. 273.e1–273.e8, 2016.

[10] E. Lefkou, A. Mamopoulos, T. Dagklis, C. Vosnakis, D. Roussos, and G. Girardi, “Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy,” *The Journal of Clinical Investigation*, vol. 126, no. 8, pp. 2933–2940, 2016.

[11] S. S. Pierangeli, M. G. Lazzaroni, A. Kuzenko et al., “Hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid syndrome or antibodies,” *Thrombosis and Haemostasis*, vol. 117, no. 25, pp. 6948–6951, 2011.

[12] M. L. Bertolaccini, G. Contento, R. Lennen et al., “The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug,” *Blood*, vol. 115, no. 11, pp. 2292–2299, 2010.

[13] K. Schreiber, K. Breen, H. Cohen et al., “Hydroxychloroquine to Improve Pregnancy Outcome in Women with AntiThrombophilic Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies,” *Seminars in Thrombosis and Hemostasis*, vol. 43, no. 6, pp. 562–571, 2017.

[14] M. L. Bertolaccini, G. Contento, R. Lennen et al., “Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome,” *Journal of Autoimmunity*, vol. 75, pp. 30–38, 2016.

[15] N. Müller-Calleja, D. Manukyan, A. Canisius, D. Strand, and K. J. Lackner, “Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase,” *Annals of the Rheumatic Diseases*, vol. 76, no. 5, pp. 891–897, 2017.

[16] A. Mekinian, M. G. Lazzaroni, A. Kuzenko et al., “The efficacy of hydroxychloroquine for obstetrical outcome in antiphospholipid syndrome: data from a European multicenter retrospective study,” *Autoimmunity Reviews*, vol. 14, no. 6, pp. 498–502, 2015.